{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:25:09Z","timestamp":1788751509459,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019700","name":"Al-Nahrain University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178195","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:29:29Z","timestamp":1758760169000},"page":"178195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exploring Prima-1MET as a single agent or in combination with tamoxifen in breast cancer cells in vitro"],"prefix":"10.1016","volume":"1006","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-7987","authenticated-orcid":false,"given":"Ali Haider","family":"Alhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2587-317X","authenticated-orcid":false,"given":"Shahad Ali","family":"Mudhafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-9955","authenticated-orcid":false,"given":"Shaimaa Yousif","family":"Abdulfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178195_bib2","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.21123\/bsj.2024.10135","article-title":"APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells","volume":"21","author":"Alhammer","year":"2024","journal-title":"Baghdad Sci. J."},{"key":"10.1016\/j.ejphar.2025.178195_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/wasj.2024.291","article-title":"KIF15 inhibitor suppresses the proliferation and migration, and induces the apoptosis of breast cancer cells","volume":"7","author":"Alhammer","year":"2025","journal-title":"World Acad. Sci. J."},{"key":"10.1016\/j.ejphar.2025.178195_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020228","article-title":"Triple-negative breast cancer progression and drug resistance in the context of epithelial-mesenchymal transition","volume":"17","author":"B\u0142aszczak","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178195_bib4","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.febslet.2014.04.017","article-title":"Mutant p53 reactivation by small molecules makes its way to the clinic","volume":"588","author":"Bykov","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2025.178195_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178195_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102445","article-title":"Tailoring adjuvant endocrine therapy in early breast cancer: when, how, and how long?","volume":"110","author":"Cucciniello","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2025.178195_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf020","article-title":"Interaction between estrogen receptors and p53: a broader role for tamoxifen?","volume":"166","author":"Das","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178195_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178195_bib10","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1038\/s41467-021-27142-6","article-title":"Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)","volume":"12","author":"Degtjarik","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178195_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1835","article-title":"Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo","volume":"10","author":"Dibra","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2025.178195_bib12","doi-asserted-by":"crossref","DOI":"10.1063\/5.0183327","article-title":"Testing the cytotoxic potential of biosynthesized nanoparticles using Conocarpus erectus Leaves against human breast cancer cells","volume":"2922","author":"Fathi","year":"2024","journal-title":"AIP Conf. Proc."},{"key":"10.1016\/j.ejphar.2025.178195_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11581","article-title":"Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin","volume":"7","author":"Fust\u00e9","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178195_bib14","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejphar.2025.178195_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2025.178195_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31048-7","article-title":"Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246","volume":"8","author":"Haffo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178195_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12688\/f1000research.108628.2","article-title":"p53 mutation as plausible predictor for endocrine resistance therapy in luminal breast cancer","volume":"11","author":"Halim","year":"2022","journal-title":"F1000Res"},{"key":"10.1016\/j.ejphar.2025.178195_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejphar.2025.178195_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178195_bib20","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178195_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2889","article-title":"Choosing the right cell line for breast cancer research","volume":"13","author":"Holliday","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib23","article-title":"Acridine orange\/ethidium bromide (AO\/EB) staining to detect apoptosis","volume":"2006","author":"Kasibhatla","year":"2006","journal-title":"CSH Protoc."},{"key":"10.1016\/j.ejphar.2025.178195_bib24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41416-021-01561-0","article-title":"APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation","volume":"125","author":"Kobayashi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178195_bib25","first-page":"5436","article-title":"Cytotoxic potential of neem (Azadirachta indica A. Juss) oil","volume":"7","author":"Lafta","year":"2023","journal-title":"Tropical J. Nat. Prod. Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lfs.2013.12.009","article-title":"Premature senescence in human breast cancer and colon cancer cells by tamoxifen-mediated reactive oxygen species generation","volume":"97","author":"Lee","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.178195_bib27","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178195_bib28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejphar.2025.178195_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/humu.22556","article-title":"Analysis of TP53 mutation status in human cancer cell lines: a reassessment","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejphar.2025.178195_bib30","article-title":"Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic-associated molecular subtypes and genomic mutations","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178195_bib31","doi-asserted-by":"crossref","first-page":"36689","DOI":"10.18632\/oncotarget.5385","article-title":"PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178195_bib32","first-page":"249","article-title":"APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice","volume":"11","author":"Liang","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178195_bib33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/gutjnl-2015-309770","article-title":"APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178195_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ejphar.2025.178195_bib35","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178195_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2025.178195_bib37","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-Mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178195_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10637-023-01380-5","article-title":"The p53 reactivator PRIMA-1(MET) synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells","volume":"41","author":"Mohammed","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2025.178195_bib22","first-page":"3862","article-title":"Effects of combined PRIMA-1MET with 5-Fluorouracil in BxPC-3 pancreatic cancer cells expressing mutant TP53","volume":"20","author":"Mohammed","year":"2022","journal-title":"NeuroQuantology"},{"key":"10.1016\/j.ejphar.2025.178195_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122648","article-title":"Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma","volume":"9","author":"Montalto","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178195_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejphar.2025.178195_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178195_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125559","article-title":"Targeting the p53\/xCT\/GSH axis with PRIMA-1(Met) combined with sulfasalazine shows therapeutic potential in chronic lymphocytic leukemia","volume":"26","author":"Pasino","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178195_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9120172","article-title":"PRIMA-1 and PRIMA-1(Met) (APR-246): from mutant\/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies","volume":"9","author":"Perdrix","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178195_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13058-020-01318-2","article-title":"MDM2 inhibition in combination with endocrine therapy and CDK4\/6 inhibition for the treatment of ER-positive breast cancer","volume":"22","author":"Portman","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117351","article-title":"Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer","volume":"179","author":"Qayoom","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178195_bib46","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1128\/MCB.23.13.4713-4727.2003","article-title":"p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1","volume":"23","author":"Rocha","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178195_bib47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178195_bib48","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.febslet.2008.03.057","article-title":"Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest","volume":"582","author":"Sun","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2025.178195_bib49","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2025.178195_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.09.053","article-title":"Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007","volume":"414","author":"Synnott","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178195_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-011-1934-z","article-title":"Molecular insights on basal-like breast cancer","volume":"134","author":"Valentin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178195_bib52","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/0008-5472.CAN-06-0511","article-title":"p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","article-title":"The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178195_bib54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-22-0275","article-title":"APR-246 enhances colorectal cancer sensitivity to radiotherapy","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178195_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178195_bib56","first-page":"11","article-title":"Anti-bacterial and anti-tumoral activities of Spirulina Platensis extracellular extract","volume":"18","author":"Zaki","year":"2022","journal-title":"Malays. J. Med. Health Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:34:13Z","timestamp":1780202053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"alternative-id":["S0014299925009495"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178195","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Prima-1MET as a single agent or in combination with tamoxifen in breast cancer cells in vitro","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178195"}}